REPLY: Schenck Process Selects Storm Reply to Develop an Innovative Cloud IoT Platform to Make Machines and Processes Smarter
31.3.2022 10:30:00 EEST | Business Wire | Press release
Storm Reply, specialised in the design and implementation of innovative cloud-based solutions and services and AWS Premier Consulting Partner, supported the leading mechanical engineering company Schenck Process in developing the serverless, modular IoT platform CONiQ Cloud.
CONiQ Cloud is the IoT backbone to make machines and processes smarter. It provides digital process solutions to save production time and deliver critical insights in near real-time, creating a broader window of opportunity for data-driven responses.
Schenck Process is evolving from a traditional machine builder to an Industry 4.0 company, going beyond its traditional business field and positioning itself as a digital service provider and pioneer for its customers. Schenck Process enables data-driven optimisation of processes through the use of IoT and cloud computing. With this purpose in mind, Storm Reply selected the appropriate AWS building blocks and developed an individual Industrial IoT (IIoT) solution that meets the customer-specific requirements.
Standard core IoT functions available include: organisational and machine management, analytics integration, machine and process data visualisation, email notification, and secure data connection and streaming to CONiQ Monitor - Schenck Process' condition-based monitoring sensor system.
Both the serverless architecture and the high degree of automation offer economic advantages and the modular structure, on the other hand, enables the flexible adaptation to specific customer needs, paving the way for further innovations. These include real-time insights from production processes, the use of machine learning for early warning of deviations from standard processes during production; focusing on predictive quality assurance and maintenance scenarios.
"We intend to reach more customers and integrate additional processes with existing clients, and that's where the modular structure and flexibility of integration pays off," says Benedikt Trumpff, Head of iQ Systems and Services at Schenck Process. "What we ultimately offer our customers with the CONiQ Cloud is additional production time – that is more valuable than anything else. With the new functionalities we are implementing, we can also develop algorithms that deliver Process Insights-as-a-Service, which translate process data into actionable insights that would otherwise be inaccessible to customers."
The CONiQ Cloud enables the processing of data from various sources as it can be connected to any customer system and easily scaled with further functionalities. This creates the conditions for building intelligent machines and establishing smarter processes.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] is specialised in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly focused companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media, and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
Storm Reply
Storm Reply is the Reply Group company specializing in design and implementation of cloud-based solutions and services. Having a consolidated experience in Cloud IaaS, PaaS and SaaS architectures, Storm Reply provides an end to end set of services for Cloud Adoption, Development of new applications and management full services of their cloud environment. Having deep competencies and experiences on management of complex cloud projects, Storm Reply helps customers to implement their Strategy Cloud Approach. In particular, Storm Reply offers services on Cloud Strategy and Migration, Cloud Native Applications development and Cloud Service Management. www.storm.reply.com
Schenck Process
Schenck Process is a leading global provider of sustainable products, integrated solutions and services for bulk solids. Headquartered in Darmstadt, Germany, the Group is represented in over 20 countries on five continents and focuses primarily on the market segments "Food", "Mining", "Chemical and Performance Materials" and "Infrastructure and Energy". The product range includes solutions for industrial weighing, feeding, conveying, screening, mixing and extruding as well as digital applications.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005045/en/
Contact information
Media contact:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Aaron Miani
a.miani@reply.com
Tel. +442077306000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom